Estudo randomizado | Gencitabina vs. nab-paclitaxel combinado com cisplatina como tratamento de primeira linha em pacientes com câncer de mama metastático triplo-negativo.
18 Jul, 2022 | 12:27h
Comentário no Twitter
Gemcitabine or nab-paclitaxel in combination with cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer: results of a randomized phase 3 trial.https://t.co/RKZYdLRbHq#CancerResearch @natrescancer pic.twitter.com/CrCOCJ2HMu
— Nature Communications (@NatureComms) July 13, 2022